Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
University of California, San Francisco
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center
Centre Oscar Lambret
Vanderbilt-Ingram Cancer Center
Emory University
Fujian Medical University
Sun Yat-sen University
University of Michigan Rogel Cancer Center
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Mayo Clinic
Washington University School of Medicine
Eye & ENT Hospital of Fudan University
Eye & ENT Hospital of Fudan University
Eye & ENT Hospital of Fudan University
University of Michigan Rogel Cancer Center
Aarhus University Hospital
Sun Yat-sen University
Shandong Tumor Hospital
Guangdong Provincial People's Hospital
Qilu Hospital of Shandong University
Sun Yat-sen University
Fudan University
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
All India Institute of Medical Sciences, Jodhpur
The Clatterbridge Cancer Centre NHS Foundation Trust
Fudan University
Fudan University
University of Aarhus
Uppsala University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
University College, London
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
University of Cincinnati
Fudan University
Fujian Medical University
The University of Texas Health Science Center at San Antonio
Shanghai Jiao Tong University School of Medicine
Nanfang Hospital, Southern Medical University
Fudan University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Barbara Ann Karmanos Cancer Institute
CEL-SCI Corporation
Hubei Cancer Hospital
Roswell Park Cancer Institute
Sun Yat-sen University
Clinical Center of Vojvodina